Invetx was a Boston-based veterinary biotechnology company developing protein-based therapeutics — species-specific, half-life-extended monoclonal antibodies (mAbs) — for chronic conditions in companion animals (dogs and cats). Its integrated platform spanned antibody discovery, optimization, Fc-variant half-life extension, development and manufacturing, with lead program IVX-01. Backed by GV, F-Prime Capital, Novo Holdings, Eight Roads, Anterra Capital, Casdin Capital and Tekla, Invetx was acquired by Dechra Pharmaceuticals in July 2024 for up to $520M. It exposes no public API, developer, or documentation surface, and its standalone website (invetx.com) has been decommissioned since the acquisition; this profile is retained as a network lead / portfolio record.
Invetx * is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Animal Health, and Veterinary.
aid: invetx
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source: []
generated: '2026-07-22'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/invetx.png
name: Invetx *
description: Invetx was a Boston-based veterinary biotechnology company developing protein-based therapeutics — species-specific,
half-life-extended monoclonal antibodies (mAbs) — for chronic conditions in companion animals (dogs and cats). Its integrated
platform spanned antibody discovery, optimization, Fc-variant half-life extension, development and manufacturing, with lead
program IVX-01. Backed by GV, F-Prime Capital, Novo Holdings, Eight Roads, Anterra Capital, Casdin Capital and Tekla, Invetx
was acquired by Dechra Pharmaceuticals in July 2024 for up to $520M. It exposes no public API, developer, or documentation
surface, and its standalone website (invetx.com) has been decommissioned since the acquisition; this profile is retained
as a network lead / portfolio record.
url: https://raw.githubusercontent.com/api-evangelist/invetx/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: dechra
x-acquired-date: '2024-07-18'
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Animal Health
- Veterinary
- Monoclonal Antibodies
- Therapeutics
- Acquired
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/invetx-domain-security.yml
x-enrichment:
date: '2026-07-19'
status: backfilled
pass: local-v1
note: backfilled from .gitignore signal + verified work evidence
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.